Pulse Biosciences (NASDAQ:PLSE) Trading Down 1.4% – What’s Next?

Shares of Pulse Biosciences, Inc (NASDAQ:PLSE) were down 1.4% during trading on Thursday . The stock traded as low as $14.02 and last traded at $14.10. Approximately 218,228 shares were traded during trading, an increase of 34% from the average daily volume of 162,256 shares. The stock had previously closed at $14.30.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Pulse Biosciences presently has a consensus rating of “Hold” and an average price target of $22.00.

Pulse Biosciences Price Performance

The stock’s 50-day moving average price is $14.10 and its 200-day moving average price is $15.56. The company has a market cap of $955.56 million, a P/E ratio of -12.48 and a beta of 1.69.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.02.

Institutional Investors Weigh In On Pulse Biosciences

Several institutional investors have recently made changes to their positions in the stock. Portolan Capital Management LLC acquired a new stake in Pulse Biosciences during the third quarter worth approximately $1,809,000. Geode Capital Management LLC raised its holdings in Pulse Biosciences by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 499,464 shares of the company’s stock valued at $7,538,000 after acquiring an additional 33,744 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Pulse Biosciences during the 2nd quarter valued at $466,000. Brooklyn Investment Group grew its holdings in shares of Pulse Biosciences by 5,313.1% during the 3rd quarter. Brooklyn Investment Group now owns 30,259 shares of the company’s stock worth $536,000 after purchasing an additional 29,700 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of Pulse Biosciences by 53.4% during the 3rd quarter. UBS Group AG now owns 76,856 shares of the company’s stock worth $1,360,000 after purchasing an additional 26,739 shares in the last quarter. 76.95% of the stock is currently owned by institutional investors.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.